Why can my lipoprotein(a) level change from 85 nmol/L to 132 nmol/L if it is supposed to be stable over time?

Why Your Lp(a) Can Vary from 85 to 132 nmol/L

While Lp(a) is predominantly genetically determined and traditionally considered stable, recent evidence demonstrates clinically significant intraindividual variability that can affect risk classification—your readings of 85 to 132 nmol/L represent a 55% change that falls within the observed biological and analytical variation documented in multiple recent studies.

Understanding Lp(a) Stability: The Traditional View vs. Current Evidence

The 2021 Canadian Cardiovascular Society guidelines state that Lp(a) levels are "generally stable throughout life" and recommend measuring it only once in a lifetime 1. This recommendation is based on the fact that Lp(a) is over 90% genetically determined and not influenced by age, sex, fasting state, inflammation, or lifestyle factors 1.

However, this "measure once" paradigm is now being challenged by emerging data.

Recent Evidence on Lp(a) Variability

Magnitude of Variation

Multiple 2025-2026 studies reveal substantial intraindividual variability:

• In a large academic health system study of 11,669 patients, 24.9% showed Lp(a) changes ≥10 mg/dL over median 4.5 years 2
• A tertiary lipid clinic study found intraindividual coefficients of variation of 19.0% (mean-based) and 33.6% (log-transformed), exceeding laboratory analytical variation 3
• In the STAR-Lp(a) study, 64.7% of patients showed changes ≥10% of baseline, and 44.3% showed changes ≥20% 4

Your Specific Case

Your change from 85 to 132 nmol/L represents a 55% increase, which places you in the upper range of documented variability but is not unprecedented. Both values fall within the "borderline to elevated" range where variability appears most pronounced.

Factors Associated with Greater Lp(a) Variability

Based on the most recent evidence 2, the following factors predict higher likelihood of Lp(a) changes ≥10 mg/dL:

• Female sex (statistically significant, P<0.001)
• History of atherosclerotic cardiovascular disease (P=0.003)
• Statin therapy (P=0.003)
• Elevated LDL-C levels ≥100 mg/dL (P<0.001)

Important caveat: Lipid-lowering therapy was associated with higher variability in pediatric studies 5, though statins do not meaningfully lower Lp(a) levels 1.

Clinical Implications for Risk Classification

Risk Threshold Considerations

Using established thresholds:

• Your lower value (85 nmol/L): Below the 100 nmol/L threshold used by Canadian guidelines 1
• Your higher value (132 nmol/L): Above the 100 nmol/L threshold, placing you in the elevated risk category

This represents a clinically meaningful reclassification. Studies show that 12.4% of patients experience cardiovascular risk reclassification when using repeat measurements 3, with particular instability in the borderline range (50-120 nmol/L) 5.

Practical Recommendations

Should You Repeat the Test?

Yes, consider one additional measurement if:

• You fall near decision thresholds (which you do)
• You're being evaluated for Lp(a)-lowering therapies
• You have any of the risk factors for variability listed above

The peak-value strategy shows highest concordance (87-92% agreement) with alternative approaches 5, suggesting that using your higher value (132 nmol/L) for risk stratification may be most appropriate.

Management Based on Your Levels

Both your values exceed 50 mg/dL (approximately 100 nmol/L), which triggers the following recommendations 1:

1. More intensive management of all modifiable cardiovascular risk factors
2. Earlier and more aggressive LDL-C lowering (target <1.8 mmol/L if very high risk, <2.6 mmol/L if high risk)
3. Consider coronary artery calcium scoring if you're in borderline-to-intermediate risk category 6
4. Maximize statin therapy to highest tolerated dose
5. Consider PCSK9 inhibitors if you have established cardiovascular disease or very high risk 1

Common Pitfalls to Avoid

1. Don't dismiss the higher value as "lab error" without considering biological variability
2. Don't assume Lp(a) is completely stable based on older paradigms
3. Don't focus solely on Lp(a)—it's not currently a treatment target; focus on aggressive LDL-C lowering 1
4. Don't repeat measurements frequently—if you do retest, wait at least 1 year

Sources of Variability

The observed variation likely reflects:

• Biological variability (documented in untreated patients 5)
• Analytical variability (laboratory measurement variation)
• Potential seasonal effects (modest variation observed in some studies 7)
• Medication effects (if you're on lipid-lowering therapy)

The key point: Even if some variability is analytical noise, the persistence of variability across multiple studies and the differential patterns across risk categories support a genuine biological component 5.